银屑病、葡萄膜炎和炎症性肠病患者中脊柱关节炎筛查工具:范围综述
本范围综述遵循PRISMA指南,检索PubMed、Embase和Web of Science至2022年1月,共识别13种银屑病关节炎筛查工具、2种葡萄膜炎脊柱关节炎筛查工具和3种炎症性肠病脊柱关节炎筛查工具;所有工具均为患者自评问卷(Dublin葡萄膜炎评估工具为医生用算法),完成时间平均不足5分钟;各工具在主要验证队列中灵敏度和特异度可比,但二次验证研究中通常较低且变异明显;结论指出现有工具异质性和局限性,尚无工具可通用。
要点
- identified 13种银屑病关节炎筛查工具、2种葡萄膜炎SpA筛查工具和3种IBD SpA筛查工具。
- 除Dublin葡萄膜炎评估工具为医生用算法外,其余均为患者自评问卷,完成时间平均不足5分钟。
- 各工具在主要验证队列中灵敏度和特异度可比,但二次验证研究中通常较低且变异明显。
核心结论
- 现有SpA筛查工具存在异质性和局限性,虽在特定目标人群中显示应用前景,但尚无工具可通用所有有SpA风险的外肌骨骼表现患者。
- 未来研究应探索通用型患者自评SpA筛查工具的效用,该工具需适用于银屑病、葡萄膜炎或IBD患者、易于使用和理解并涵盖SpA所有临床领域。
研究设计与样本
- 本研究为范围综述,遵循系统综述和Meta分析首选报告条目(PRISMA)指南。
- 检索PubMed、Embase和Web of Science,时间从建库至2022年1月。
主要发现
- 共识别13种银屑病关节炎筛查工具、2种葡萄膜炎SpA筛查工具和3种IBD SpA筛查工具。
- 所有筛查工具均为患者自评问卷,仅Dublin葡萄膜炎评估工具为医生用算法。
- 问卷在长度、评分方法、截断值和包含的SpA特征范围上各不相同,平均完成时间不足5分钟。
- 在三个人群中,这些筛查工具在主要验证队列中的灵敏度和特异度可比。
- 二次验证研究中灵敏度和特异度通常较低,且队列间变异明显。
局限性
- 现有SpA筛查工具存在异质性和局限性。
- 尚无工具可通用所有有SpA风险的外肌骨骼表现患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Extramusculoskeletal manifestations of spondyloarthritis (SpA) may precede the development of articular features. Patients seen in ophthalmology, dermatology, and gastroenterology clinics with uveitis, psoriasis, or inflammatory bowel disease (IBD) may have undiagnosed SpA. We set out to identify and evaluate screening tools for SpA in patients with psoriasis, uveitis, and IBD and determine factors that influence the performance of these instruments. METHODS: This scoping review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Embase, and Web of Science were searched from inception to January 2022. RESULTS: We identified 13 screening tools for psoriatic arthritis, 2 SpA screening tools for uveitis, and 3 SpA screening tools for IBD. All screening tools were patient-oriented questionnaires except for the Dublin Uveitis Evaluation Tool, a physician-applied algorithm. The questionnaires varied in length, scoring method, cutoff score, and spectrum of included SpA features. Average completion time was less than five minutes. Across the three patient populations, the sensitivities and specificities of these screening tools were comparable in the primary validation cohorts. Sensitivities and specificities were generally lower in secondary validation studies, with marked variability among cohorts. CONCLUSION: Our results highlight the heterogeneity and limitations of existing SpA screening tools. Although these tools show promise for use within a specific target population, none are generalizable to all patients with extramusculoskeletal manifestations at risk of SpA. Future studies should explore the utility of a generic patient-oriented SpA screening tool that can be applied to patients with psoriasis, uveitis, or IBD; is easy to use and comprehend; and captures all clinical domains of SpA.
引用
- Kesarwani V, Sinnappan S, Husni ME, et al. Screening Tools for Spondyloarthritis in Patients With Psoriasis, Uveitis, and Inflammatory Bowel Disease: A Scoping Review. Arthritis Care Res (Hoboken). 2024. PMID: 38303576. doi:10.1002/acr.25308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。